{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:29:13Z","timestamp":1740104953205,"version":"3.37.3"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T00:00:00Z","timestamp":1513555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["WEUSKOP5496"],"award-info":[{"award-number":["WEUSKOP5496"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>A composite end point (CE) measuring neonatal benefit was created for use in tocolytic randomized controlled trials with rates assessed using data from one referral hospital. The goal of this study was to assess wider generalizability of the CE, using data from multiple integrated delivery networks, creating a cohort of linked mother\u2010neonate pairs to understand neonatal outcomes in a broad population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective data on births (2001\u20102012) were collected from 4 US integrated delivery networks in the COMparative effectiveness PAtient Safety and Surveillance (COMPASS) Research Network, and linked mother\u2010neonate pairs were identified. The CE was analyzed for all in\u2010hospital singleton neonates at \u226524\u00a0weeks of gestational age (GA) born to mothers aged \u226445\u00a0years at a referral hospital or hospital with &gt;2000 annual births.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The CE analyses included 56\u00a0485 eligible mother\u2010neonate pairs; frequency of the CE decreased from 89% to 66% between GA weeks 24 and 29 and further decreased to &lt;14% for infants born &gt;34\u00a0weeks of GA. Composite end point rates were 20% to 30% lower at 24 to 30\u00a0weeks of GA in COMPASS compared with Medical University of South Carolina but were similar by 31\u00a0weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The COMPASS Network enabled evaluation of the CE across a large population demonstrating that the CE findings could be replicated beyond a single hospital and the potential for lower CE frequency. Based on this, an adaptive design was adopted for randomized controlled trials, specifically sample size reestimation to mitigate against the risk of lower outcome rates, highlighting the use of real\u2010world data in drug development.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4371","type":"journal-article","created":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T09:16:00Z","timestamp":1513588560000},"page":"213-220","source":"Crossref","is-referenced-by-count":1,"title":["Assessing a composite end point for new tocolytics in clinical trials: Data from 4 <scp>US<\/scp> integrated delivery networks"],"prefix":"10.1002","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-7770","authenticated-orcid":false,"given":"Jeanne M.","family":"Pimenta","sequence":"first","affiliation":[{"name":"Real World Evidence and Epidemiology GSK  Uxbridge Middlesex UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Brinkley","sequence":"additional","affiliation":[{"name":"IQVIA, Danbury Conn. &amp; Research Triangle Park  NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy H.","family":"Montague","sequence":"additional","affiliation":[{"name":"Clinical Statistics GSK  Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen J.","family":"Beach","sequence":"additional","affiliation":[{"name":"Maternal Neonatal Health Unit GSK  Durham NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Mack","sequence":"additional","affiliation":[{"name":"IQVIA, Danbury Conn. &amp; Research Triangle Park  NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,12,18]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60820-4"},{"key":"e_1_2_8_3_1","unstructured":"World Health Organization.Every newborn: an action plan to end preventable deaths [Internet].2014. Available fromhttp:\/\/apps.who.int\/iris\/bitstream\/10665\/127938\/1\/9789241507448_eng.pdf?ua=1. Accessed April 12 2016."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4755-10-S1-S2"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60074-4"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1251816"},{"volume-title":"Preterm Birth: Causes, Consequences, and Prevention","year":"2007","author":"Institute of Medicine (US) Committee on Understanding Premature Birth and Assuring Healthy Outcomes","key":"e_1_2_8_7_1"},{"key":"e_1_2_8_8_1","unstructured":"Royal College of Obstetricians and Gynaecologists.Green\u2013top Guideline No. 1b. [Internet]. Tocolytic drugs for women in preterm labour;2011. Available fromhttp:\/\/www.rcog.org.uk\/womens\u2010health\/clinical\u2010guidance\/tocolytic\u2010drugs\u2010women\u2010preterm\u2010labour\u2010green\u2010top\u20101b. Accessed April 20 2016."},{"key":"e_1_2_8_9_1","unstructured":"US Food and Drug Administration: Advisory Committee for Reproductive Health Drugs.1998. Available fromhttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/98\/transcpt\/3407t1.rtfAccessed April 20 2016."},{"key":"e_1_2_8_10_1","unstructured":"US Food and Drug Administration: Advisory Committee for Reproductive Health Drugs.2012. Available fromhttp:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/reproductivehealthdrugsadvisorycommittee\/ucm287987.pdf. Accessed cited 20 April 2016."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.12593"},{"key":"e_1_2_8_12_1","unstructured":"GSK.NCT02377466: a phase III efficacy and safety study of intravenous retosiban versus placebo for women in spontaneous preterm labor[Internet].2015. Available fromhttps:\/\/www.clinicaltrials.gov\/ct2\/results?term=NCT02377466. Accessed April 20 2016."},{"key":"e_1_2_8_13_1","unstructured":"GSK.NCT02292771: a randomized study comparing the efficacy and safety of retosiban versus atosiban for women in spontaneous preterm labour[Internet].2015. Available fromhttps:\/\/www.clinicaltrials.gov\/ct2\/results?term=NCT02292771. Accessed April 20 2016."},{"key":"e_1_2_8_14_1","unstructured":"KupermanGJ SpurrC FlamminiS BatesD GlaserJ.A clinical information systems strategy for a large integrated delivery network. Proceedings \/ AMIA Annual Symposium.2000;438\u201342."},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10995-011-0902-x"},{"issue":"12","key":"e_1_2_8_16_1","first-page":"1","article-title":"Births: final data for 2014","volume":"64","author":"Hamilton BE","year":"2015","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000130837.57743.7b"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2012.06.051"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12646"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-0542"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4371","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T16:09:50Z","timestamp":1694275790000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,18]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/pds.4371"],"URL":"https:\/\/doi.org\/10.1002\/pds.4371","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2017,12,18]]}}}